用于勃起功能障碍的干细胞疗法。

Stem-cell therapy for erectile dysfunction.

作者信息

Yiou R

机构信息

APHP, Urology Department, Henri Mondor Teaching Hospital, 51 av du Maréchal de Lattre de Tassigny, 94010 Créteil, France. Tel.: +33 (0)1.49.81.25.59; E-mail:

出版信息

Biomed Mater Eng. 2017;28(s1):S81-S85. doi: 10.3233/BME-171627.

Abstract

Stem cell-based therapies have been recently investigated in the field of organic erectile dysfunctions, such as those associated with diabetes or the treatment of prostate cancer. The overall aim is to repair the repair the underlying penile cellular damage. Here, we review the rationale behind the use of stem cells injection in post-radical prostatectomy erectile dysfunction (pRP-ED).Radical prostatectomy for prostate cancer induces complex neurologic and vascular injuries that cause one of the most difficult-to-treat forms of erectile dysfunction. Evidence from animal models replicating pRP-ED suggests that intracavernous injection of autologous bone marrow mononuclear cells (BM-MNCs) may represent the first curative approach. Several clinical trials are ongoing and two of them have been completed with encouraging results.

摘要

基于干细胞的疗法最近在器质性勃起功能障碍领域得到了研究,比如与糖尿病相关的勃起功能障碍或前列腺癌的治疗。总体目标是修复阴茎潜在的细胞损伤。在此,我们回顾了在根治性前列腺切除术后勃起功能障碍(pRP-ED)中使用干细胞注射的基本原理。前列腺癌根治术会导致复杂的神经和血管损伤,从而引发最难治疗的勃起功能障碍形式之一。复制pRP-ED的动物模型的证据表明,海绵体内注射自体骨髓单个核细胞(BM-MNCs)可能是第一种治愈方法。多项临床试验正在进行中,其中两项已经完成,结果令人鼓舞。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索